addS

Thursday 24 September 2015

Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges: Market Research, Insights, outlook and survey report

Players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages. The Chinese biopharmaceutical market is presented as follows:

By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)

By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
A wealth of financial information is provided including:
Company financials, sales & revenue figures
China GDP, economic growth, export (bulk drug, formulations) figures
Indian health expenditure as a function of GDP
Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
Projected figures of strategic emerging industry GDP percentage contribution

To Browse a Full Report with TOC@ http://www.researchmoz.us/pharmaceutical-industry-in-china-to-2020-an-in-depth-analysis-of-multinational-and-chinese-biopharma-companies-industry-trends-environment-regulation-market-drivers-restraints-opportunities-challenges-report.html

SWOT, Economic and Business Environment specifics include:
Key strengths, weaknesses and threats influencing leading player position within the market
Top Five Contract Pharmaceutical Export Markets of China
Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
Multinational penetration into the Chinese Pharma Market
Comprehensive product portfolios, R&D activity and pipeline therapeutics
M&A activity and future strategies of top Chinese pharmacos
Economic indicators, trade policy, merchandise and commercial trade statistics
Gross Domestic Product of China, historic and projection analysis
Chinese economic outlook in comparison to advanced economies
Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
Prescription drug sales distribution channels in China
Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

Amoytop Biotech
Active Pharmaceutical Products
Beijing Continent Pharmaceuticals
FusoGen Pharmaceuticals
Shanghai Huaguan Biochip
SiBiono GeneTech
Abbott
AstraZeneca
Boehringer Ingelheim
Eli Lilly
GlaxoSmithKline
Johnson & Johnson Medical
Merck
Novartis
Pfizer
Roche

To Download Sample Report With TOC@ http://www.researchmoz.us/enquiry.php?type=sample&repid=368558

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
Current market facts, figures and product lines of key players in the industry
An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
Knowledge of how the Chinese pharma market will integrate into the global healthcare market
Information on key regulatory and government policies
Data on levels of private and publically funded biopharma studies in China
Strategies on how to adapt and restructure current business models to this industry
This report tackles key concerns to the Chinese biopharmaceutical market such as:
Lack of regulatory policy and legislation
Reimbursement schemes and payers concerns
Funding and government sponsorship issues
International scepticism of Chinese safety and efficacy therapeutic profiles
This report will tell you if the companies mentioned are:
Strong, competitive players
Pooling their resources for specific growth and therapeutic areas
Investing strategically in R&D
Have a history of strategic M&A activity

To Enquire Regarding This Report@ http://www.researchmoz.us/enquiry.php?type=enquiry&repid=368558

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us: 

Mr. Nachiket

State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Blog: http://dynamicmarketresearch.blogspot.com/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074

No comments:

Post a Comment